Separation, identification and application of novel steroid saponin in allium macrostemon
By isolating and identifying the saponin T from the saponin, and preparing the compound by ultrasound-assisted extraction and column chromatography, the shortcomings of existing drugs in terms of neuroprotection are solved and effective protection of nerve damage is achieved, especially It has shown significant neuroprotective effects in diseases such as depression, Alzheimer's disease and anxiety.
Patent Information
- Application Number
- CN202411082590.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-08
- Publication Date
- 2024-11-22
AI Technical Summary
Existing drugs used to improve nerve damage have problems such as long-term onset, long-lasting side effects and limited treatment effects, especially in neurodegenerative diseases such as depression, Alzheimer's disease and anxiety, which lack effective and side effects. Small neuroprotective drugs.
A neosteroid saponin substance, Salmon T, was isolated from the scalmon, and the compound was prepared by ultrasonic assisted extraction, column chromatography and other methods, confirming that it has a neuroprotective effect.
Salmon saponin T has good protective activity on Glu-induced HT22 cell damage, significantly reduces intracellular ROS levels and apoptosis rates, and provides a potential basis for drug development against neuronal damage.
Smart Images

Figure CN118994294A_ABST
Abstract
Description
Technical field:
[0001] The invention belongs to the field of medical technology, and specifically relates to the separation, purification and preparation of a new steroidal saponin substance in Xiebai, and the determination of the neuroprotective activity thereof. Background technology:
[0002] Hippocampal neuron damage and death are associated with a variety of neurological diseases, including neurodegenerative diseases such as depression, Alzheimer's disease and anxiety. Currently, the drugs used in clinical practice to improve nerve damage still have problems such as long onset time, persistent side effects, and limited therapeutic effects. Therefore, it is particularly urgent to find effective drugs with few side effects and neuroprotective effects.
[0003] Studies have shown that oxidative stress and cell apoptosis are closely related to nerve damage. Excessive oxidative stress produces a large amount of reactive oxygen species (ROS), leading to further tissue damage and neuronal dysfunction, while excessive ROS can lead to cell apoptosis.
[0004] Xiebai is the dried bulb of Allium macrosAemon Bunge or Allium chinenseG.Don of the genus Allium of the Liliaceae family, which has the effects of regulating qi, widening the chest, promoting yang, and dispersing nodules. Through in-depth research on the effective ingredients in Xiebai in recent years, it was found that steroidal saponins are the important pharmacological material basis for Xiebai to exert its effects, which has gradually intensified the research on steroidal saponins in Xiebai.
[0005] So far, according to the research literature on the chemical components of Allium macrostemon, there are no reports on the compound Allium macrostemon saponin T and its neuroprotective effects. Summary of the invention:
[0006] The present invention innovatively discovers and successfully separates Xiebai saponin T (spirostane-25(27)-en-2α,3β-diol-3-O-β-D-xylopyranosyl(1→3)-β-D-glucopyranosyl(1→4)-β-D-galactopyranoside, macrostemonoside T or spirostane-25(27)-ene-2α,3-β-diol-3-O-β-D-xylopyranosyl(1→3)-β-D-glucopyranosyl(1→4)-β-D-galactopyranoside) from Xiebai samples.
[0007] The compound Allium saponin T in the present invention has been preliminarily confirmed to have a neuroprotective effect.
[0008] The invention provides a compound in Xiebai and also provides a method for separating the compound from Xiebai.
[0009] The present invention first provides a new compound, which is named as Xanthoxylum saponin T, and has the molecular formula: C 44 H 70 O 18 , the structural formula is as follows:
[0010]
[0011] The separation method of the compound of the present invention comprises the following steps:
[0012] (1) The dried Xiebai sample was crushed and passed through a 40-mesh sieve, and the dried Xiebai powder was dried. The dried Xiebai powder was soaked in petroleum ether (60-90°C) at a solid-liquid ratio of 1:5 for 1 hour, and ultrasonic-assisted extraction was performed at room temperature for 30 minutes at 100W, and the extraction was repeated 6 times. The medicinal material residue after petroleum ether extraction was added to 80% ethanol solution at a solid-liquid ratio of 1:5, and soaked for 1 hour, and ultrasonic-assisted extraction was performed at 100W for 30 minutes, and the extraction was repeated 6 times. The filtrate was combined, concentrated under reduced pressure at 35°C until there was no alcohol taste, and then freeze-dried to obtain the 80% ethanol extract of Xiebai.
[0013] (2) The ethanol extract in step (1) is dissolved in 2 times the amount of distilled water, and then extracted with petroleum ether, dichloromethane and n-butanol in a gradient manner, each solvent is extracted four times, and the extracts are combined. The n-butanol portion is decompressed at 35° C. until it does not contain n-butanol, and then freeze-dried to obtain the n-butanol extraction portion of Xiebai.
[0014] (3) The n-butanol extract in step (2) was chromatographed on a 200-300 mesh silica gel column (Qingdao Ocean Chemical Co., Ltd.) using a mobile phase of dichloromethane-methanol-water in a volume ratio of 5:2:1 to 13:8:2 for gradient elution to obtain Fr.3.1 to 3.12, respectively.
[0015] (4) Fr.3.6 in step (3) was subjected to ODS (YMC, Japan) column chromatography, and gradient elution was performed using methanol-water in a ratio of 20:80 to 70:30 as the eluent to obtain three components, namely Fr.3.6.1 to 3.6.3
[0016] (5) Fr.3.6.3 in step (4) was subjected to ODS (YMC Co., Ltd., Japan) column chromatography, and gradient elution was performed using methanol-water in a ratio of 60:40 to 90:10 as the eluent to obtain the compound Allium macrostemon saponin T.
[0017] The present invention further provides the use of the compound in the preparation of an anti-nerve injury drug, specifically, the use of the compound in the preparation of a drug for preventing, treating or improving nerve injury.
[0018] As a preferred embodiment of the present invention, the neuron damage-related diseases include depression, Alzheimer's disease, anxiety disorder, etc.
[0019] The beneficial effects of the present invention compared to the prior art are:
[0020] The invention separates a steroidal saponin compound, Allium macrostemon saponin T, from Allium macrostemon. The compound has good protective activity against Glu-induced HT22 cell damage. The invention lays a foundation for the development and utilization of drugs against neuron damage. Description of the drawings:
[0021] Attached Figure 1 The COSY (red bold), HMBC (blue arrow) and NOESY (red arrow) correlation of the oxalis saponin T of the present invention
[0022] Attached Figure 2 HR-ESI-MS spectrum of the oxalis saponin T of the present invention
[0023] Attached Figure 3 The present invention is the oxalis saponin T 1 H-NMR (600MHz, Pyridine-d5) spectrum
[0024] Attached Figure 4 The present invention is the oxalis saponin T 13 C-NMR (150MHz, Pyridine-d5) spectrum
[0025] Attached Figure 5 The HMQC spectrum of the oxalis saponin T of the present invention is
[0026] Attached Figure 6 The HMBC spectrum of the oxalis saponin T of the present invention is
[0027] Attached Figure 7 The COSY spectrum of the Xiebai saponin T of the present invention is
[0028] Attached Figure 8 The NOESY spectrum of the Xiebai saponin T of the present invention is
[0029] Attached Fig. 9 The effect of the oxalis saponin T on the level of ROS in HT22 cells induced by Glu
[0030] Attached Fig.10 The effect of the present invention on the apoptosis of HT22 cells induced by Glu Specific implementation method:
[0031] Below I will further illustrate the separation and purification method of the present invention in conjunction with specific embodiments, but the scope of protection of the present invention is not limited thereto.
[0032] Example 1: Separation and preparation of the compound of the present invention, Xanthoxylum saponin T
[0033] The structural formula of the compound Xylella saponin T of this embodiment is as follows:
[0034]
[0035] 1. The separation and preparation method of the compound comprises the following steps:
[0036] (1) Crush the dried sample of Xiebai and pass it through a 40-mesh sieve, and dry the dried powder of Xiebai. Soak the dried powder of Xiebai in petroleum ether (60-90°C) at a solid-liquid ratio of 1:5 for 1 hour, perform 100W ultrasonic-assisted extraction at room temperature for 30 minutes, filter, and repeat 6 times. Soak the residue of the medicinal material after petroleum ether extraction in 80% ethanol solution at a solid-liquid ratio of 1:5 for 1 hour, perform 100W ultrasonic-assisted extraction for 30 minutes, filter, and repeat 6 times, and combine the filtrate.
[0037] The mixture was concentrated under reduced pressure at 35°C until there was no alcohol taste, and then freeze-dried to obtain a 80% ethanol extract of Allium macrostemon.
[0038] (2) The ethanol extract in step (1) is dissolved in 2 times the amount of distilled water, and then extracted with petroleum ether, dichloromethane and n-butanol in a gradient manner, each solvent is extracted four times, and the extracts are combined. The n-butanol portion is decompressed at 35° C. until it does not contain n-butanol, and then freeze-dried to obtain the n-butanol extraction portion of Xiebai.
[0039] (3) The n-butanol extract in step (2) was chromatographed on a 200-300 mesh silica gel column (Qingdao Ocean Chemical Co., Ltd.) using a mobile phase of dichloromethane-methanol-water in a volume ratio of 5:2:1 to 13:8:2 for gradient elution to obtain Fr.3.1 to 3.12, respectively.
[0040] (4) Fr.3.6 in step (3) was subjected to ODS (YMC, Japan) column chromatography, and gradient elution was performed using methanol-water in a ratio of 20:80 to 70:30 as the eluent to obtain three components, namely Fr.3.6.1 to 3.6.3
[0041] (5) Fr.3.6.3 in step (4) was subjected to ODS (YMC Co., Ltd., Japan) column chromatography, and gradient elution was performed using methanol-water in a ratio of 60:40 to 90:10 as the eluent to obtain the compound Allium macrostemon saponin T.
[0042] 2. Structural identification of the obtained compounds
[0043] It is a white amorphous powder. It is positive in the reaction with Molish and Liebermann-Burchard, but negative in the reaction with Ehrlich reagent. After heating with 10% concentrated H2SO4-EtOH on a thin layer silica gel plate, it turns purple-red. After standing for a period of time, it finally turns yellow-green, indicating that the compound may be a spirostanol saponin. The m / z of positive ion HR-ESI-MS is: 909.4487 [M+Na] + (theoretical value is 909.4460, Figure 2 ), combined with its 1 H and 13 C spectrum, confirming that its molecular formula is C 44 H 70 O 18 1H-NMR (δppm, 600MHz, Pyridine-d5) data of the compound (Table 1, Figure 2 , Figure 3 ) in the high field region indicated the presence of two characteristic signals of tertiary methyl protons at δH 1.10 (3H, s, Me-18), 1.00 (3H, s, Me-19) and one characteristic signal of secondary methyl proton at δH 1.42 (3H, d, J = 6.42 Hz, Me-21). 13 C-NMR (δppm, 150MHz, Pyridine-d5) data suggested the presence of 44 carbon signals, of which 27 carbon signals were assigned to sapogenins and 17 carbon signals were assigned to three sugar molecules (Table 1, Figure 4 ). There are three methyl signals at δC 17.00, 23.61 and 14.85, which are assigned to C-18, C-19 and C-21 respectively. It is also found that the methyl signal of C-27 is missing on the spirostanyl sapogenin nucleus. The two terminal olefin proton signals are at δH 4.80 (1H, s) and 4.83 (1H, s), and they are remotely correlated with δC 145.03 (C-25), 65.50 (C-26) and 32.34 (C-24), respectively (HMBC, Figure 6), so it is determined that there is a double bond in C25-C27. The proton signal of Me-21, δH1.42 (3H, d, J = 6.42 Hz), has long-range correlations with δC 63.46, 41.03 and 110.17, which are assigned to C-17, C-20 and C-22, respectively; the proton signal of Me-18, δH 1.10 (3H, s), has long-range correlations with δC4 0.49, 43.31, 55.71 and 63.46, which are assigned to C-12, C-13, C-14 and C-17, respectively; the proton signal of Me-19, δH 1.00 (3H, s), has long-range correlations with δC39.25, 39.81, 36.53 and 37.24, which are assigned to C-1, C-5, C-9 and C-10, respectively. Since the hydrogen signal of Me-18 (δH 1.10) is in the downfield compared to Me-19 (δH 1.00), H-5 is determined to be α-type. 1 H- 1 H COSY spectrum ( Figure 7 ), H2-1 / H-2 / H-3 are correlated, and combined with the HMQC spectrum ( Figure 5 ), so δC 67.45 is assigned to C-2, and δC 82.27 is assigned to C-3. Since δC 67.45 is a signal of oxygen-linked methylene carbon, it suggests that C-2 may be connected to a hydroxyl group. At the same time, considering that C-3 is affected by the glycosylation shift, the chemical shift moves to 82.28 ppm downfield, so it is speculated that C-3 is connected to the sugar group. In the NOESY spectrum ( Figure 8 ) is correlated with the Me-19 (β-type) signal, thus confirming that the C-2 hydroxyl group is α-type.
[0044] The type of sugar molecules was determined by acid hydrolysis experiments, and the results showed that the ratio of galactose, glucose and xylose was 1:1:1. According to the three isomeric proton signals δH 4.94 (1H, d, J = 7.62 Hz, H-1a), 5.31 (1H, d, J = 7.68 Hz, H-1b) and 5.34 (1H, d, J = 7.74 Hz, H-1c), it was inferred that there were three sugar molecules, and the correlation between HMQC and the three isomeric carbons was 103.08, 106.62 and 107.55 ppm, respectively, and according to the coupling constants of the three, it can be judged that they are all β configurations. In the HMBC spectrum, the terminal proton signal δH 4.94 (H-1a) of galactose a has a long-range correlation with the C-3 of the parent nucleus (δC 82.27), so it is judged that the sugar is connected to the C-3 position of the sapogenin parent nucleus, which is consistent with the previous speculation; the terminal proton δH5.31 (H-1b) of glucose b has a long-range correlation with C-4a (δC 70.33) of galactose a, and it is speculated that its connection mode is 1→4; the terminal proton δH 5.34 (H-1c) of xylose c has a long-range correlation with C-3b (δC 79.82) of glucose b, and it is speculated that its connection mode is 1→3. In summary, the structure of the compound was determined to be spirostan-25(27)-ene-2α,3β-diol-3-O-β-D-xylopyranosyl(1→3)-O-β-D-glucopyranosyl(1→4)-O-β-D-galactopyranoside and named Macrostemonoside T.
[0045] Table 1. 1 H-NMR and 13 C-NMR data
[0046]
[0047]
[0048] Example 2: Protective effect of the compound Allium saponin T of the present invention on Glu-induced injury of mouse hippocampal neuron cells HT22.
[0049] 1. Drug preparation
[0050] Allium saponin T was dissolved in DMEM high-glucose medium to make the stock solution concentration 10mM / mL, and diluted to the following concentrations: 0.1μM, 0.5μM, 1.0μM, 2.0μM, 5.0μM, 10.0μM, 20.0μM, 40.0μM. Glu was mixed evenly with DMEM high-glucose medium to make the solution concentration 20mM.
[0051] 2. Cell culture
[0052] HT22 cells were grown in DMEM high-glucose medium containing 10% fetal bovine serum (FBS) and 1% penicillin / streptomycin at 37°C and 5% CO2 humidified air. The complete medium was replaced every 48 h. All experiments were performed when the cells reached the logarithmic growth phase.
[0053] 3. MTT assay to determine the effect of Xylella saponin T on cell viability
[0054] HT22 cells were cultured at 1×10 5 The number of cells was inoculated in a 96-well plate, and the supernatant was discarded after incubation in an incubator for 24 h. The cells were pre-treated with different concentrations of Allium saponin T. The control group and the Glu group were given an equal amount of DMEM high-glucose medium. After incubation in an incubator for 24 h, the supernatant was discarded, and the cells were treated with 20 mM Glu. The control group was given an equal amount of DMEM high-glucose medium. After incubation in an incubator for 24 h, 20 μL of MTT solution (5 mg / mL) was added to each well under light-proof conditions. After incubation in an incubator for 3.5 h, the supernatant was discarded, 100 μL of DMSO was added to each well to dissolve formazan, and the absorbance at 490 nm was measured using an enzyme reader after sufficient shaking.
[0055] 4. Effect of Allium tuberosum saponin T on ROS levels in HT22 cells induced by Glu
[0056] HT22 cells in the logarithmic growth phase were diluted to 2×10 5 After the concentration of cells / mL was reached, the cells were inoculated in a 6-well plate, and cell culture and administration were performed in the same manner as in step 3. 24 hours after modeling, the old culture medium was removed, and PBS buffer (pH=7.4) containing 5 μmol / L DCFH-DA reactive oxygen fluorescent probe was added, and the cells were incubated at 37°C for 30 minutes; the fluorescent probes that did not enter the cells were washed with PBS buffer and observed under a fluorescence microscope.
[0057] 5. Effect of Allium tuberosum saponin T on Glu-induced apoptosis of HT22 cells
[0058] HT22 cells in the logarithmic growth phase were diluted to 2×10 5 After the concentration of cells / mL was reached, the cells were inoculated in a 6-well plate, and cell culture and administration were performed in the same manner as in step 3. After 24 hours of modeling, the old culture medium was discarded, and the cells were fixed with 4% paraformaldehyde at room temperature for 20 minutes. The paraformaldehyde fixative was removed by aspiration, and the cells were washed 2-3 times with PBS. 1 mL of 5 mg / L Hoechst 33258 was added to each well and reacted at room temperature for 30 minutes in the dark. The dye was discarded, and the cells were washed 2-3 times with PBS, and observed under a fluorescence microscope.
[0059] 4. Data processing
[0060] The experimental data were compared between groups using the mean ± SD method and one-way analysis of variance (ANOVA) for statistical analysis. p < 0.05 or p < 0.01 was considered statistically significant.
[0061] 5. Results
[0062] 5.1 Effect of Allium saponin T on cell viability
[0063] The activity of Allium tuberosum saponin T on Glu-induced HT22 cell injury is shown in Table 2. As shown in the table, cell viability was significantly decreased after Glu treatment ( *** p<0.001), and administration of Xylella saponin T showed better protective activity ( ### p<0.001, ## p<0.01, # p<0.05). It can be seen that Allium saponin T has a good activity in protecting HT22 cell damage induced by Glu.
[0064] 5.2 Effect of Allium saponin T on Glu-induced ROS levels in HT22 cells
[0065] Results Fig. 9 Compared with the blank control group, the green fluorescence intensity of HT22 cells induced by Glu in the model group increased, indicating that the level of intracellular ROS increased; compared with the model group, Allium tuberosum saponin T could reduce the fluorescence intensity and reduce the level of intracellular ROS. From the perspective of intracellular ROS level, the protective effect of Allium tuberosum saponin T on Glu-induced HT22 cell damage was further verified.
[0066] 5.3 Effect of Allium saponin T on Glu-induced apoptosis of HT22 cells
[0067] Results Fig.10 The nuclei of the blank control group were normal blue. Compared with the blank control group, most of the nuclei of Glu-induced HT22 cells in the model group were densely stained. Compared with the model group, Allium tuberosum saponin T could significantly reduce the fluorescence intensity of the nuclei in a dose-dependent manner, indicating that Allium tuberosum saponin T could alleviate cell apoptosis and thus produce a neuroprotective effect.
[0068] Table 2 Comparison of the activity of Allium tuberosum saponin T on Glu-induced HT22 cell injury
[0069]
[0070] The present invention is described in detail above in combination with preferred embodiments and exemplary examples. However, it should be noted that these specific embodiments are only illustrative explanations of the present invention and do not constitute any limitation on the protection scope of the present invention. Without exceeding the spirit and protection scope of the present invention, various improvements, equivalent substitutions or modifications may be made to the technical content of the present invention and its embodiments, which all fall within the protection scope of the present invention. The protection scope of the present invention shall be subject to the attached claims.
Claims
1. A novel compound, characterized in that The compound is named spirostane-25(27)-en-2α,3β-diol-3-O-β-D-xylopyranosyl(1→3)-β-D-glucopyranosyl(1→4)-β-D-galactopyranoside (spirostane-25(27)-en-2α,3β-diol-3-O-β-D-xylopyranosyl(1→3)-β-D-glucopyranosyl(1→4)-β-D-galactopyranoside, macrostemonoside T or scutellariae saponin T), and its molecular formula is: C 44 H 70 O 18 , the structural formula is as follows:
2. The method for preparing a compound according to claim 1, characterized in that: The method comprises: A. The dried sample of Xiebai was crushed and passed through a 40-mesh sieve, and then degreased using petroleum ether (60-90° C.). The residue of the medicinal material after extraction with petroleum ether was extracted with 80% ethanol solution by ultrasonic assisted extraction, and freeze-dried to obtain Xiebai 80% ethanol extract. B. The ethanol extract of Allium macrostemon was dissolved in water, and then extracted with petroleum ether, dichloromethane and n-butanol in a gradient manner, and the n-butanol portion was concentrated until it did not contain n-butanol, and freeze-dried to obtain the n-butanol extraction portion of Allium macrostemon. C. After the n-butanol extract was dissolved, it was separated by silica gel column chromatography and gradient eluted with dichloromethane-methanol-water. During the elution process, TLC was used to track and merge, and a total of 12 fractions Fr.3.1~12 were obtained. D. Fr.3.6 was subjected to ODS column chromatography and gradient eluted with methanol and water as the mobile phase to obtain three elution parts Fr.3.6.1~3. E.Fr.3.6.3 was purified by ODS column chromatography using methanol and water as the mobile phase for gradient elution to obtain compound Allium macrosaponin T.
3. The compound isolated from Xiebai according to claim 2, characterized in that: The processing operation in step A includes: crushing the dried Xiebai sample and passing it through a 40-mesh sieve, drying the dried Xiebai powder, adding petroleum ether (60-90° C.) to the dried Xiebai powder at a solid-liquid ratio of 1:5 and soaking it for 1 hour, performing 100W ultrasonic-assisted extraction for 30 minutes at room temperature, filtering, and repeating 6 times, adding 80% ethanol solution to the medicinal material residue after petroleum ether extraction at a solid-liquid ratio of 1:5 and soaking it for 1 hour, performing 100W ultrasonic-assisted extraction for 30 minutes, filtering, and repeating 6 times, combining the filtrate, concentrating under reduced pressure at 35° C. until there is no alcohol taste, and freeze-drying to obtain a 80% ethanol extract of Xiebai.
4. The compound isolated from Xiebai according to claim 2, characterized in that: The number of extractions with each solvent in step B is four times, the extraction time is 2 hours, and the concentrate is concentrated under reduced pressure.
5. The n-butanol extract in step C was chromatographed on a 200-300 mesh silica gel column with dichloromethane-methanol-water as the mobile phase in a volume ratio of 5:2:1 to 13:8:2 for gradient elution to obtain Fr.3.1 to 3.12, respectively.
6. Fr.3.6 in step D was subjected to ODS column chromatography and gradient elution was performed using methanol-water in a ratio of 20:80 to 70:30 as the eluent to obtain three components, namely Fr.3.6.1 to 3.6.
3.
7. Fr.3.6.3 in step E is subjected to ODS column chromatography, and gradient elution is performed using methanol-water in a ratio of 60:40 to 90:10 as the eluent to obtain the compound Allium macrostemon saponin T. The compound Allium saponin T according to claim 1 is an amorphous white powder.
9. Use of the compound according to claim 1 in the preparation of drugs for resisting nerve damage.
10. The use according to claim 9, characterized in that: The application is application in the preparation of drugs for preventing, treating or improving diseases related to neuronal damage.
11. The use according to claim 10, characterized in that: The neuron damage-related diseases include depression, Alzheimer's disease, anxiety disorder, etc.
12. A pharmaceutical composition, comprising the compound of claim 1, and optionally comprising one or more auxiliary materials, wherein the auxiliary materials include excipients, and the excipients include any one or more of a binder, a filler, and a lubricant.
Citation Information
Patent Citations
Polygonatum sibiricum steroid sapogenin and preparation method and application thereof
CN110507662A
Usage of steroi saponin for preventing and curing senile dementia and new steroid saponin
CN1212966A
Theraputic methods and uses of sapogenins and their derivatives
WO2003082893A2
